| __timestamp | Arrowhead Pharmaceuticals, Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 24419536 | 302156000 |
| Thursday, January 1, 2015 | 34718089 | 402271000 |
| Friday, January 1, 2016 | 40998209 | 476593000 |
| Sunday, January 1, 2017 | 32022880 | 554336000 |
| Monday, January 1, 2018 | 19110051 | 604353000 |
| Tuesday, January 1, 2019 | 26556257 | 680924000 |
| Wednesday, January 1, 2020 | 52275890 | 737669000 |
| Friday, January 1, 2021 | 80981000 | 759375000 |
| Saturday, January 1, 2022 | 124431000 | 854009000 |
| Sunday, January 1, 2023 | 90932000 | 937300000 |
| Monday, January 1, 2024 | 98761000 |
Unveiling the hidden dimensions of data
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. BioMarin Pharmaceutical Inc. and Arrowhead Pharmaceuticals, Inc. have shown contrasting trends in their SG&A expenses from 2014 to 2023. BioMarin's expenses have consistently increased, peaking at approximately 937% of Arrowhead's 2014 expenses by 2023. This reflects BioMarin's aggressive expansion and investment in administrative capabilities. In contrast, Arrowhead's SG&A expenses have seen a more volatile trajectory, with a significant spike in 2022, reaching nearly 124% of their 2014 expenses. This fluctuation could indicate strategic shifts or increased operational costs. Notably, BioMarin's data for 2024 is missing, leaving room for speculation on their future financial strategies. Understanding these trends provides valuable insights into the financial health and strategic priorities of these pharmaceutical giants.
Selling, General, and Administrative Costs: BeiGene, Ltd. vs Arrowhead Pharmaceuticals, Inc.
Viatris Inc. or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Walgreens Boots Alliance, Inc.
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Alpine Immune Sciences, Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs TG Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Rhythm Pharmaceuticals, Inc.
BioMarin Pharmaceutical Inc. and Arrowhead Pharmaceuticals, Inc.: A Detailed Gross Profit Analysis
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Novavax, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Grifols, S.A. and Arrowhead Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Corcept Therapeutics Incorporated vs Arrowhead Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Arrowhead Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and MannKind Corporation